ArticleMolecular psychiatry2021
Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [
Article in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06977308 (A Multimodal Imaging Study of Dopamine in Early Psychosis), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multimodal Imaging Study of Dopamine in Early Psychosis
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Eating disorders and disordered eating symptoms in individuals at clinical high risk for psychosis: a systematic review and meta-analysis.Eating and weight disorders : EWD · 2024Pooled it
- SN/VTA neuromelanin signal is associated with subclinical paranoia irrespective of familial risk for psychosis.Schizophrenia (Heidelberg, Germany) · 2026Article
- Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far.Frontiers in psychiatry · 2026Review
- Reward Processing in Mood Disorders and Schizophrenia: A Neurodevelopmental Framework.Annual review of clinical psychology · 2025Review
- Spurious autobiographical memories of psychosis: a dopamine-gated neuroplasticity account for relapse and treatment-resistant psychosis.Psychological medicine · 2025Review
- The dopaminergic basis of negative symptoms in schizophrenia: an addendum.Molecular psychiatry · 2025Article
- Amphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation.Schizophrenia bulletin · 2024Observational
- Generalizability and Out-of-Sample Predictive Ability of Associations Between Neuromelanin-Sensitive Magnetic Resonance Imaging and Psychosis in Antipsychotic-Free Individuals.JAMA psychiatry · 2024Article
- Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies.International journal of molecular sciences · 2023Review
- Parsing neurobiological heterogeneity of the clinical high-risk state for psychosis: A pseudo-continuous arterial spin labelling study.Frontiers in psychiatry · 2023Article
- Dopamine and glutamate in individuals at high risk for psychosis: a meta-analysis of in vivo imaging findings and their variability compared to controls.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients at clinical high-risk (CHR) for psychosis show elevations in [
Indexed as
Identifiers
33154566What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.